Publication | Closed Access

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

MedicineImmunologyGynecologyImmune Checkpoint InhibitorCancer TreatmentImmunotherapyOncologyGynecology OncologyOvarian Cancer